{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:02:55Z","timestamp":1792029775309,"version":"4.4.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Pharma AG (DE)"},{"name":"Bayer Pharma AG (DE)"},{"name":"Hannover Medical School (DE)"},{"name":"German Heart Foundation (DE)"},{"name":"German Research Foundation (DE)","award":["REBIRTH"],"award-info":[{"award-number":["REBIRTH"]}]},{"name":"German Research Foundation (DE)","award":["REBIRTH"],"award-info":[{"award-number":["REBIRTH"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0184888","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T17:33:56Z","timestamp":1505842436000},"page":"e0184888","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-2221","authenticated-orcid":true,"given":"Jochen","family":"Dutzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert-Jonathan","family":"Musmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Haertl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Marcus","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sonnenschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Sedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.004046","article-title":"The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study","volume":"129","author":"AE Moran","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"J Bauersachs","year":"2015","journal-title":"Hypertension"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"B Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"34","key":"ref4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"G Montalescot","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"C Zwadlo","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"e0145958","DOI":"10.1371\/journal.pone.0145958","article-title":"Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"HH Le","year":"2016","journal-title":"PLoS One"},{"issue":"24","key":"ref7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"IH de Boer","year":"2011","journal-title":"JAMA"},{"issue":"31","key":"ref8","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/eurheartj\/eht235","article-title":"The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?","volume":"34","author":"J Bauersachs","year":"2013","journal-title":"Eur Heart J"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"L Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"ref10","article-title":"Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","author":"P Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"31","key":"ref11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"B Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"ref12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"G Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","article-title":"Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors","volume":"34","author":"D Pruthi","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2005.10.017","article-title":"Impact of plasma aldosterone levels for prediction of in-stent restenosis","volume":"97","author":"T Amano","year":"2006","journal-title":"Am J Cardiol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"F Ivanes","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijcard.2005.03.078","article-title":"Eplerenone suppresses neointimal formation after coronary stent implantation in swine","volume":"107","author":"K Wakabayashi","year":"2006","journal-title":"Int J Cardiol"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"H Kursaklioglu","year":"2004","journal-title":"Ann Acad Med Singapore"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/FJC.0b013e31826f5535","article-title":"Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice","volume":"60","author":"A Raz-Pasteur","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"ref19","first-page":"761","article-title":"Vascular wound healing and neointima formation induced by perivascular electric injury in mice","volume":"150","author":"P Carmeliet","year":"1997","journal-title":"Am J Pathol"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1006\/jmcc.2000.1238","article-title":"A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia","volume":"32","author":"M Sata","year":"2000","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00395-012-0261-9","article-title":"Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation","volume":"107","author":"JM Daniel","year":"2012","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2007.061","article-title":"Clinical chemistry reference database for Wistar rats and C57\/BL6 mice","volume":"388","author":"O Boehm","year":"2007","journal-title":"Biol Chem"},{"issue":"4914","key":"ref23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.2526370","article-title":"Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury","volume":"245","author":"JS Powell","year":"1989","journal-title":"Science"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"D Fraccarollo","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction","volume":"67","author":"A Gueret","year":"2016","journal-title":"Hypertension"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0024-3205(96)00331-1","article-title":"Stability study on renal type I mineralocorticoid receptor","volume":"59","author":"MD Galigniana","year":"1996","journal-title":"Life Sci"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"H2035","DOI":"10.1152\/ajpheart.00552.2010","article-title":"Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression","volume":"300","author":"J Favre","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCRESAHA.115.308269","article-title":"Endothelial Mineralocorticoid Receptor Mediates Diet-Induced Aortic Stiffness in Females","volume":"118","author":"G Jia","year":"2016","journal-title":"Circ Res"},{"key":"ref29","article-title":"Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Neointimal Hyperplasia and Suppresses Macrophage Inflammation Through SGK1-AP1\/NF-kappabeta Pathways","author":"JY Sun","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"P Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0184888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T02:23:34Z","timestamp":1719455014000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0184888"}},"subtitle":[],"editor":[{"given":"Diego","family":"Alvarez de la Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0184888","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]}}}